Columbus, Ohio-based Deep Lens Inc., which focuses on artificial intelligence (AI) to help in clinical trial recruitment, reported that it has closed a $14 million series A financing, led by Northpond Ventures. Also joining were existing investors Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners. News of the round comes three months after Deep Lens closed its venture capital-led seed equity round, bringing the total raised to $17.5 million.

Intrinsic Therapeutics Inc. closed a $52 million series growth equity financing led by Questa Capital. Intrinsic's Barricaid Anular Closure device received premarket approval from the U.S. FDA in February and the funds will be used to propel the device's strategic market release, according to the Woburn, Mass.-based company. Returning investors in this round included New Enterprise Associates, Greenspring Associates, Quadrille and Delos Capital.